Major
Probable
Description
Both escitalopram and hydroxychloroquine prolong the QT interval; their concurrent use markedly increases the risk of potentially fatal arrhythmias.
Mécanisme
Both agents block hERG channels in a dose-dependent manner, producing additive prolongation of the QTc interval.
Signification clinique
FDA safety communications highlight QT prolongation risk for both drugs; their combination is considered high risk in patients with risk factors.
Prise en charge
Avoid combination or use with extreme caution; obtain baseline ECG, monitor QTc throughout therapy, and correct electrolytes.